Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERILE WATER FOR INJECTION vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Water serves as a vehicle for dissolving or diluting drugs for parenteral administration; it has no intrinsic pharmacologic activity. It maintains body fluid balance and is essential for cellular homeostasis.
The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.
Vehicle for reconstitution of parenteral drugs,Fluid replacement in patients with isotonic fluid deficits when used with appropriate electrolytes (e.g., 5% dextrose in water),Off-label: Diluent for irrigation solutions
FDA-approved for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) in patients with end-stage renal disease (ESRD),Off-label uses include acute kidney injury (AKI) requiring dialysis in select settings
Sterile water for injection is not administered directly; it is used as a diluent or solvent for medications. There is no standard therapeutic dose. Administration is via intravenous, intramuscular, or subcutaneous route as required for reconstitution.
Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.
The elimination half-life of water is approximately 7-14 days in healthy adults, reflecting the turnover rate of total body water (TBW). In clinical use, administered water equilibrates rapidly with TBW (half-life <1 hour) and is then subject to normal renal excretion, with a terminal half-life of 7-14 days as part of body water turnover. Clinically, water is not considered to have a meaningful elimination half-life due to rapid equilibration and homeostatic regulation.
Calcium: terminal half-life 4-6 hours in patients with normal renal function; magnesium: terminal half-life 3-5 hours. Prolonged in renal impairment.
Water is not metabolized; it is distributed in the body and excreted primarily by the kidneys via urine, with minor losses through skin, lungs, and feces.
The solution components (bicarbonate, lactate, dextrose, electrolytes) are not metabolized by the liver; bicarbonate and lactate are buffer precursors converted via endogenous pathways; dextrose is absorbed and metabolized systemically; electrolytes are regulated by renal and non-renal mechanisms.
Renal excretion of free water following equilibration with total body water; no active elimination. >99% eliminated via kidneys as urine, with minor losses via insensible routes (skin, lungs) and feces (<1% combined).
Primarily renal excretion; ~70% of calcium dose and ~60% of magnesium dose excreted unchanged in urine. Fecal elimination accounts for ~20% and ~30%, respectively. Biliary excretion is minimal.
0%. Water does not bind to plasma proteins. It is freely diffusible across capillary and cell membranes.
Calcium: ~40-50% bound to albumin; magnesium: ~25-30% bound to albumin. Binding decreases in hypoalbuminemia.
Approximately 0.55-0.60 L/kg in adults (total body water: ~42 L in 70 kg). This represents the volume of fluid into which water distributes, essentially the total body water compartment. In clinical pharmacokinetics, Vd is not applicable for water as it is the solvent of the body.
Calcium: 0.25-0.4 L/kg; magnesium: 0.5-0.7 L/kg. Indicates distribution into extracellular fluid and bone (calcium) or intracellular and bone (magnesium).
Intravenous: 100%. Subcutaneous: ~100% (water is absorbed completely due to small molecular size and passive diffusion). Oral: ~100% (water is absorbed from gastrointestinal tract via osmosis and aquaporins, with negligible first-pass metabolism).
Intravenous: 100%. Intraperitoneal: ~70-80% (dependent on dwell time and concentration). Oral: ~30-40% for calcium and ~40-60% for magnesium (varies with formulation and GI factors).
No dose adjustment is needed for renal impairment as sterile water for injection is not systemically active and is used solely as a vehicle.
For GFR 30-60 m L/min: reduce amino acid dose to 0.8 g/kg/day. For GFR <30 m L/min: reduce to 0.6 g/kg/day. Lipids may require adjustment based on triglyceride levels. Avoid in severe renal failure unless on dialysis.
No dose adjustment is needed for hepatic impairment as sterile water for injection is not systemically active and is used solely as a vehicle.
Child-Pugh A: no adjustment. Child-Pugh B: reduce amino acids to 1.0 g/kg/day. Child-Pugh C: avoid use or reduce to 0.5 g/kg/day with close monitoring for encephalopathy. Lipids may be given at standard doses but monitor triglycerides.
Weight-based dosing is not applicable; used as a diluent per medication-specific instructions. Volume of sterile water for injection should be adjusted based on the required dose of the reconstituted drug and the patient's weight and clinical condition.
Neonates and infants: amino acids 2.0-3.0 g/kg/day, lipids 1.0-3.0 g/kg/day. Children 1-10 years: amino acids 1.5-2.5 g/kg/day, lipids 1.0-2.0 g/kg/day. Administer via continuous infusion over 24 hours. Monitor serum triglycerides, bilirubin, and liver function.
No specific dose adjustment needed for elderly patients; use the minimal volume necessary to achieve desired drug concentration, considering potential fluid and electrolyte imbalances and reduced renal function.
Use caution; start at low end of adult dosing (amino acids 1.2 g/kg/day, lipids 1.0 g/kg/day). Monitor renal function (creatinine clearance) and fluid status due to increased risk of fluid overload. No specific dose adjustments except based on renal function.
For sterile water for injection: Do not use for intravenous injection without first adjusting isotonicity, as administration of free water into the bloodstream can cause severe hemolysis and potentially fatal complications.
Not for intravenous use. Peritoneal dialysis should be performed under strict aseptic technique to prevent peritonitis. Use only in patients with intact peritoneal membrane and no contraindications to peritoneal dialysis.
Risk of hemolysis and electrolyte imbalance when administered intravenously without addition of solutes; monitor for fluid overload and hyponatremia; caution in patients with impaired renal function, cardiac failure, or conditions predisposing to fluid retention.
Monitor serum electrolytes, glucose, and acid-base status frequently. Risk of hyperglycemia, hypernatremia, hypokalemia, hypocalcemia, and metabolic alkalosis. Peritonitis and catheter-related infections are major complications. Avoid in patients with severe lactic acidosis or hypokalemia. Use caution in patients with glucose intolerance or liver disease.
Absolute: None. Relative: Severe renal impairment (risk of volume overload), known hypersensitivity to any component (if present in the container), and conditions where saline or electrolyte-containing solutions are required.
Absolute: Hypersensitivity to any component, pre-existing severe metabolic alkalosis, documented non-functioning peritoneal membrane, or conditions compromising peritoneal integrity (e.g., extensive adhesions, diaphragmatic defects). Relative: Uncontrolled hyperglycemia, severe hypokalemia, or recent abdominal surgery.
No known food interactions. Sterile water for injection is intended for parenteral administration only and does not interact with dietary items.
No specific food interactions. However, patients should maintain a diet appropriate for chronic kidney disease on peritoneal dialysis, including controlled intake of potassium, phosphorus, and fluids as directed by their healthcare provider.
No fetal risk identified; sterile water for injection is isotonic and lacks pharmacological activity. No known teratogenic effects in any trimester.
Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.
Safe for use during breastfeeding. Sterile water for injection is a normal constituent of breast milk; M/P ratio not applicable.
Excreted into breast milk in low amounts; M/P ratio not established; compatible with breastfeeding with monitoring of infant electrolytes.
No dose adjustment required; pharmacokinetics of water are not altered in pregnancy.
Increased plasma volume in pregnancy may require dose adjustments; monitor serum potassium and calcium; hemofiltration dose may need increased frequency or volume.
Sterile water for injection is hypotonic and must not be administered intravenously without first being made isotonic by admixture with appropriate solutes (e.g., dextrose, saline) to prevent hemolysis. It is used for reconstitution of powdered medications and for dilution of concentrated solutions. Always verify compatibility with other drugs before mixing. Use immediately after opening; discard any unused portion as it contains no preservatives.
PHOXILLUM BK 4/2.5 is a peritoneal dialysis solution containing 4% icodextrin and 2.5% amino acids. It is used for one exchange per day in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Avoid use in patients with known hypersensitivity to icodextrin or amino acids. Monitor serum osmolality and glucose levels, as icodextrin may interfere with glucose oxidase-based glucometers, leading to falsely elevated readings. Use with caution in patients with liver disease due to potential amino acid accumulation.
This product is sterile water; do not inject it directly into a vein unless mixed with other medications as directed.,It is used to dissolve or dilute other medicines before injection.,Your healthcare provider will prepare and administer this product; do not attempt to self-administer.,Tell your pharmacist or nurse if you have any allergies or medical conditions.,Store at room temperature; do not freeze.
Use only one bag per day, typically for the long dwell (overnight).,Do not use if the solution is cloudy or the bag is damaged.,Store at room temperature, away from direct sunlight.,Monitor for signs of infection like redness, swelling, or drainage at the catheter site.,Report any unusual abdominal pain or cloudy effluent immediately.,If using a glucose meter, ensure it is not affected by icodextrin; consider using a glucose dehydrogenase-based meter.,Maintain a balanced diet as amino acids may affect protein intake needs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERILE WATER FOR INJECTION vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, answered by our medical review team.
STERILE WATER FOR INJECTION is a Irrigation Solution that works by Water serves as a vehicle for dissolving or diluting drugs for parenteral administration; it has no intrinsic pharmacologic activity. It maintains body fluid balance and is essential for cellular homeostasis.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is a Irrigation Solution that works by The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERILE WATER FOR INJECTION and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERILE WATER FOR INJECTION is: Sterile water for injection is not administered directly; it is used as a diluent or solvent for medications. There is no standard therapeutic dose. Administration is via intravenous, intramuscular, or subcutaneous route as required for reconstitution.. The standard adult dose of PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is: Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERILE WATER FOR INJECTION and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERILE WATER FOR INJECTION is classified as Category C. No fetal risk identified; sterile water for injection is isotonic and lacks pharmacological activity. No known teratogenic effects in any trimester.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is classified as Category C. Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.